Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Oxford Immunotec Global PLC    OXFD   GB00BGFBB958

OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2018 06/20/2018 06/21/2018 06/22/2018 06/25/2018 Date
14.49(c) 14.49(c) 14.08(c) 13.87(c) 13.7 Last
266 996 239 931 278 545 434 869 120 754 Volume
+1.33% 0.00% -2.83% -1.49% -1.23% Change
More quotes
Financials (USD)
Sales 2018 113 M
EBIT 2018 -22,6 M
Net income 2018 -25,6 M
Finance 2018 3,58 M
Yield 2018 -
Sales 2019 128 M
EBIT 2019 -17,1 M
Net income 2019 -20,0 M
Finance 2019 3,32 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 3,15x
EV / Sales2019 2,78x
Capitalization 359 M
More Financials
Company
Oxford Immunotec Global Plc operates as a medical diagnostics company, which develops and commercializes proprietary tests for under-served immune-regulated conditions.Its current product lines and development activities principally focus on four areas: infectious diseases, transplantation,... 
More about the company
Surperformance© ratings of Oxford Immunotec Global PL
Trading Rating : Investor Rating :
More Ratings
Latest news on OXFORD IMMUNOTEC GLOBAL PL
05/29Oxford Immunotec to Present at the Jefferies 2018 Healthcare Conference
GL
05/22Oxford Immunotec Announces Launch of the Accutix™ Brand
GL
05/01OXFORD IMMUNOTEC GLOBAL PLC : to Host Earnings Call
AC
03/01Oxford Immunotec Announces Appointment of Mark Klausner to the Board of Direc..
GL
02/27OXFORD IMMUNOTEC GLOBAL PLC : to Host Earnings Call
AC
01/08Oxford Immunotec Announces Preliminary Revenue for Fourth Quarter and Full Ye..
GL
01/03Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Confere..
GL
2017QIAGEN : and Oxford Immunotec Settle Patent Infringement Lawsuit
PR
2017Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit
GL
2017OXFORD IMMUNOTEC GLOBAL PLC : to Host Earnings Call
AC
More news
Sector news : Medical Diagnostic & Testing Equipment
06/20Merck KGaA Partners With Alibaba Health in China
DJ
06/18How U.S. tax reform rewards companies that shift profit to tax havens
RE
06/14STRYKER : Says It Isn't in Deal Talks -- WSJ
DJ
06/13STRYKER : Says It Isn't in Deal Talks With Boston Scientific -- Update
DJ
06/13STRYKER : Says It's Not in Deal Talks with Boston Scientific
DJ
More sector news : Medical Diagnostic & Testing Equipment
Latest Tweets
06/24Analysts Expect Oxford Immunotec Global PLC $OXFD Will Post Earnings of -$0.2.. 
06/22Oxford Immunotec Global $OXFD vs. IPSEN S A/S $IPSEY Head-To-Head Survey  
06/19Oxford Immunotec Global $OXFD Stock Rating Upgraded by Zacks Investment Resea.. 
06/19Reviewing IPSEN S A/S $IPSEY & Oxford Immunotec Global $OXFD  
06/18Get the latest news and updates for $WBAI $OXFD $VIAV $EVOK $ARMK automatical.. 
More tweets
Qtime:46
News from SeekingAlpha
05/01Oxford Immunotec Global PLC 2018 Q1 - Results - Earnings Call Slides 
05/01Oxford Immunotec Global's (OXFD) CEO Peter Wrighton-Smith on Q1 2018 Results .. 
05/01Oxford Immunotec Global beats by $0.05, beats on revenue 
02/27Oxford Immunotec Global's (OXFD) CEO Peter Wrighton-Smith on Q4 2017 Results .. 
02/27Oxford Immunotec Global PLC 2017 Q4 - Results - Earnings Call Slides 
Chart OXFORD IMMUNOTEC GLOBAL PL
Duration : Period :
Oxford Immunotec Global PL Technical Analysis Chart | OXFD | GB00BGFBB958 | 4-Traders
Technical analysis trends OXFORD IMMUNOTEC GLOBAL PL
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 16,2 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Peter James Wrighton-Smith Chief Executive Officer & Executive Director
Richard Alvin Sandberg Chairman
Stefan C. Linn Chief Operating Officer
Richard M. Altieri Chief Financial & Accounting Officer
Richard J. Wenstrup Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD IMMUNOTEC GLOBAL PLC-0.72%359
SARTORIUS AG44.52%10 054
MYRIAD GENETICS, INC.13.18%2 717
VAREX IMAGING CORP-8.36%1 425
DIRUI INDUSTRIAL CO LTD--.--%760
NH SPECIAL PURPOSE ACQTN 2ND CO LTD--.--%311